tekmira pipeline

July 22, 2012 By Leave a Comment

Byron Capital analyst Douglas Loe says the lawsuit between Tekmira and Alnylam, which is scheduled to be heard in Massachusetts court in October presents a "lingering risk" for Tekmira, but this risk is being offset by reduced clinical risk for all siRNAs.

Byron Capital analyst Douglas Loe says the lawsuit between Tekmira and Alnylam, which is scheduled to be heard in Massachusetts court in October presents a “lingering risk” for Tekmira, but this risk is being offset by reduced clinical risk for all siRNAs.

Filed Under:
About Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.